These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 26486613)

  • 1. A Shot in the Arm for HIV Prevention? Recent Successes and Critical Thresholds.
    Hope TJ; Marrazzo JM
    AIDS Res Hum Retroviruses; 2015 Nov; 31(11):1055-9. PubMed ID: 26486613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining biomedical preventions for HIV: Vaccines with pre-exposure prophylaxis, microbicides or other HIV preventions.
    McNicholl JM
    Hum Vaccin Immunother; 2016 Dec; 12(12):3202-3211. PubMed ID: 27679928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promise and pitfalls of pre-exposure prophylaxis for female sex workers.
    Cowan FM; Delany-Moretlwe S
    Curr Opin HIV AIDS; 2016 Jan; 11(1):27-34. PubMed ID: 26633639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High interest in a long-acting injectable formulation of pre-exposure prophylaxis for HIV in young men who have sex with men in NYC: a P18 cohort substudy.
    Meyers K; Rodriguez K; Moeller RW; Gratch I; Markowitz M; Halkitis PN
    PLoS One; 2014; 9(12):e114700. PubMed ID: 25502768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination HIV prevention interventions: the potential of integrated behavioral and biomedical approaches.
    Brown JL; Sales JM; DiClemente RJ
    Curr HIV/AIDS Rep; 2014 Dec; 11(4):363-75. PubMed ID: 25216985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What does preexposure prophylaxis mean for treatment; what does treatment mean for preexposure prophylaxis?
    Venter WD
    Curr Opin HIV AIDS; 2016 Jan; 11(1):35-40. PubMed ID: 26545265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic prevention of human immunodeficiency virus in women: practical approaches for the obstetrician and gynecologist.
    Hong JN; Farel CE; Rahangdale L
    Obstet Gynecol Surv; 2015 Apr; 70(4):284-90. PubMed ID: 25900528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Injectable agents for pre-exposure prophylaxis: lessons learned from contraception to inform HIV prevention.
    Myers JE; Ellman TM; Westhoff C
    Curr Opin HIV AIDS; 2015 Jul; 10(4):271-7. PubMed ID: 26049953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent progress in HIV vaccines inducing mucosal immune responses.
    Pavot V; Rochereau N; Lawrence P; Girard MP; Genin C; Verrier B; Paul S
    AIDS; 2014 Jul; 28(12):1701-18. PubMed ID: 25009956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of medication therapy management in preexposure prophylaxis therapy for HIV prevention.
    Ferrell KW; Woodard LM; Woodard TJ
    J Pharm Pract; 2015 Feb; 28(1):10-2. PubMed ID: 25500557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence to preexposure chemoprophylaxis: the behavioral bridge from efficacy to effectiveness.
    Amico KR
    Curr Opin HIV AIDS; 2012 Nov; 7(6):542-8. PubMed ID: 22964887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating efficacy in a randomized trial with product nonadherence: application of multiple methods to a trial of preexposure prophylaxis for HIV prevention.
    Murnane PM; Brown ER; Donnell D; Coley RY; Mugo N; Mujugira A; Celum C; Baeten JM;
    Am J Epidemiol; 2015 Nov; 182(10):848-56. PubMed ID: 26487343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Transition From Postexposure Prophylaxis to Preexposure Prophylaxis: An Emerging Opportunity for Biobehavioral HIV Prevention.
    Jain S; Krakower DS; Mayer KH
    Clin Infect Dis; 2015 Jun; 60 Suppl 3(Suppl 3):S200-4. PubMed ID: 25972505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interview With Jean-Daniel Lelièvre, PU-PH, Head of the Research Clinic of the VRI (Vaccine Research Institute).
    Lelievre JD; Ollivier-Yaniv C
    J Acquir Immune Defic Syndr; 2018 Oct; 79 Suppl 1():S8-S12. PubMed ID: 30222700
    [No Abstract]   [Full Text] [Related]  

  • 15. Statistical issues in trials of preexposure prophylaxis.
    Dunn DT; Glidden DV
    Curr Opin HIV AIDS; 2016 Jan; 11(1):116-21. PubMed ID: 26545264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel approaches in preclinical HIV vaccine research.
    Safrit JT; Koff WC
    Curr Opin HIV AIDS; 2016 Nov; 11(6):601-606. PubMed ID: 27636502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AIDS vaccines and preexposure prophylaxis: is synergy possible?
    Excler JL; Rida W; Priddy F; Gilmour J; McDermott AB; Kamali A; Anzala O; Mutua G; Sanders EJ; Koff W; Berkley S; Fast P
    AIDS Res Hum Retroviruses; 2011 Jun; 27(6):669-80. PubMed ID: 21043994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preexposure prophylaxis for the prevention of HIV transmission to women.
    Aaron E; Cohan D
    AIDS; 2013 Jan; 27(1):F1-5. PubMed ID: 22914582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knowledge, attitudes, and likelihood of pre-exposure prophylaxis (PrEP) use among US women at risk of acquiring HIV.
    Auerbach JD; Kinsky S; Brown G; Charles V
    AIDS Patient Care STDS; 2015 Feb; 29(2):102-10. PubMed ID: 25513954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Planning for HIV preexposure prophylaxis introduction: lessons learned from contraception.
    Delany-Moretlwe S; Mullick S; Eakle R; Rees H
    Curr Opin HIV AIDS; 2016 Jan; 11(1):87-93. PubMed ID: 26575146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.